PepGen Inc. (PEPG) Price & Analysis

Compare

127 Followers

PEPG Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.88 - $10.15

Previous CloseN/A

Volume7.67K

Average Volume (3M)259.40K

Market Cap

$42.31M

Enterprise Value-$20.44M

Total Cash (Recent Filing)$74.65M

Total Debt (Recent Filing)$17.86M

Price to Earnings (P/E)―

Beta1.38

Next Earnings

Nov 06, 2025

EPS Estimate

-0.71

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.70

Shares Outstanding32,799,725

10 Day Avg. Volume370,903

30 Day Avg. Volume259,405

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap-0.48

Enterprise Value/Revenue-13.70

Enterprise Value/Gross Profit57.57

Enterprise Value/Ebitda0.22

Forecast

1Y Price Target

$7.00

Price Target Upside442.64% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering4

Bulls Say, Bears Say

Bulls Say

Clinical DevelopmentThe transition of clinical sites to FREEDOM2-DM1, a Phase 2 multiple ascending dose study, accelerates the clinical timeline and potentially saves 3-6 months.

Efficacy And SafetyThe safety profile supports the value of PepGen’s EDO platform, with no adverse effects seen in kidney biomarkers or electrolyte levels.

Market PotentialIf splicing correction continues to correlate with clinical improvement, the program could attract acquisition interest due to the growing industry focus on DM1.

Bears Say

Program DiscontinuationPepGen announced it will be discontinuing development of Duchenne muscular dystrophy programs following disappointing 10mg/kg data for PGN-EDO51.

Rating And ValuationAnalyst reiterates an Underperform rating with a $1 price objective.

PepGen Inc. News

PEPG Lawsuit Alert! Class Action Lawsuit Against PepGen Inc.

A class action lawsuit was filed against PepGen Inc. ($PEPG) by Levi & Korsinsky on June 9, 2025. The plaintiffs (shareholders)...

30d ago

PEPG

PEPG Lawsuit Alert! Class Action Lawsuit Against PepGen Inc.

A class action lawsuit was filed against PepGen Inc. ($PEPG) by Levi & Korsinsky on June 9, 2025. The plaintiffs (shareholders)...

30d ago

PEPG

PepGen Inc.’s Promising Clinical Developments and Strategic Advancements Earn a Buy Rating

Analyst Ananda Ghosh of H.C. Wainwright maintained a Buy rating on PepGen Inc., retaining the price target of...

8d ago

PEPG

PepGen Inc. Reports Q2 2025 Financial Results

PepGen Inc. ( ($PEPG) ) has released its Q2 earnings. Here is a breakdown of the information PepGen...

8d ago

PEPG

PepGen Faces Legal Storm Over Drug Trial Debacle

In a dramatic turn of events, PepGen Inc. finds itself at the center of a significant legal battle...

2M ago

PEPG

PepGen Inc. Elects Directors at Annual Meeting

PepGen Inc. ( ($PEPG) ) has shared an announcement. PepGen Inc. held its 2025 Annual Meeting of Stockholders...

2M ago

PEPG

PepGen Inc.’s Strategic Shift to DM1 Program Earns Buy Rating Amid Promising Developments

Leerink Partners analyst Joseph Schwartz has maintained their bullish stance on PEPG stock, giving a Buy rating yesterday....

3M ago

PEPG

PepGen Inc. Receives Buy Rating from Ananda Ghosh Due to Strategic Focus on Promising DM1 Program

Analyst Ananda Ghosh from H.C. Wainwright reiterated a Buy rating on PepGen Inc. (PEPG – Research Report) and...

3M ago

PEPG

PepGen price target lowered to $1 from $3 at BofA

BofA lowered the firm’s price target on PepGen (PEPG) to $1 from $3 and keeps an Underperform rating...

3M ago

PEPG

PepGen to discontinue DMD programs after PGN-EDO51 did not achieve target

PepGen (PEPG) announced that based on the levels of dystrophin protein measured in the 10 mg/kg cohort of...

3M ago

PEPG

PepGen price target lowered to $8 from $14 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on PepGen (PEPG) to $8 from $14 and keeps a Buy...

3M ago

PEPG

PepGen Inc.’s Strategic Shift Amidst DMD Program Discontinuation and Competitive Challenges

In a report released yesterday, Tazeen Ahmad from Bank of America Securities reiterated a Sell rating on PepGen...

3M ago

PEPG

PepGen Inc. Discontinues DMD Programs After Trial Results

The latest update is out from PepGen Inc. ( ($PEPG) ). On May 28, 2025, PepGen Inc. announced...

3M ago

PEPG

PepGen appoints Kasra Kasraian as CTO

PepGen ( ...

3M ago

BLUE

PEPG

PEPG FAQ

What was PepGen Inc.’s price range in the past 12 months?

PepGen Inc. lowest stock price was $0.88 and its highest was $10.15 in the past 12 months.

What is PepGen Inc.’s market cap?

PepGen Inc.’s market cap is $42.31M.

When is PepGen Inc.’s upcoming earnings report date?

PepGen Inc.’s upcoming earnings report date is Nov 06, 2025 which is in 82 days.

How were PepGen Inc.’s earnings last quarter?

PepGen Inc. released its earnings results on Aug 07, 2025. The company reported -$0.7 earnings per share for the quarter, beating the consensus estimate of -$0.846 by $0.146.

Is PepGen Inc. overvalued?

According to Wall Street analysts PepGen Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does PepGen Inc. pay dividends?

PepGen Inc. does not currently pay dividends.

What is PepGen Inc.’s EPS estimate?

PepGen Inc.’s EPS estimate is -0.71.

How many shares outstanding does PepGen Inc. have?

PepGen Inc. has 32,799,725 shares outstanding.

What happened to PepGen Inc.’s price movement after its last earnings report?

PepGen Inc. reported an EPS of -$0.7 in its last earnings report, beating expectations of -$0.846. Following the earnings report the stock price went down -13.139%.

Which hedge fund is a major shareholder of PepGen Inc.?

Currently, no hedge funds are holding shares in PEPG

PepGen Inc. Stock Smart Score

Neutral

Fundamentals

Return on Equity

-85.69%

Trailing 12-Months

Asset Growth

-47.16%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

PepGen Inc.

PepGen Inc. (PEPG) is a biotechnology company focused on developing transformative therapies for patients with neuromuscular and neurological diseases. Leveraging its proprietary Enhanced Delivery Oligonucleotide (EDO) platform, PepGen aims to deliver innovative solutions that improve the delivery and efficacy of oligonucleotides. The company's core products are designed to address unmet medical needs through targeted treatments that can enhance the quality of life for patients suffering from debilitating conditions.

PepGen Inc. (PEPG) Earnings & Revenues

Historic Earnings Reports

PEPG Stock 12 Month Forecast

Average Price Target

$7.00

▲(442.64% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","9":"$9","18":"$18","4.5":"$4.5","13.5":"$13.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$7.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$1.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,4.5,9,13.5,18],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.32,1.9876923076923076,2.6553846153846155,3.323076923076923,3.9907692307692306,4.658461538461538,5.326153846153846,5.993846153846154,6.661538461538462,7.32923076923077,7.9969230769230775,8.664615384615384,9.332307692307692,{"y":10,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.32,1.756923076923077,2.193846153846154,2.6307692307692307,3.0676923076923077,3.5046153846153842,3.941538461538461,4.378461538461538,4.815384615384615,5.252307692307692,5.689230769230769,6.126153846153846,6.563076923076923,{"y":7,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.32,1.2953846153846154,1.2707692307692309,1.2461538461538462,1.2215384615384617,1.196923076923077,1.1723076923076923,1.1476923076923078,1.123076923076923,1.0984615384615384,1.073846153846154,1.0492307692307692,1.0246153846153847,{"y":1,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7.09,"date":1704067200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.62,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.9,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.91,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.07,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.48,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.97,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.79,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.29,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.15,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.31,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.47,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.32,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >